Frequency of Pulmonary Tuberculosis in Type 2 Diabetes on Insulin Therapy Presenting to MMC Mardan
DOI:
https://doi.org/10.70749/ijbr.v3i7.1890Keywords:
Pulmonary tuberculosis, Type 2 diabetes mellitus, Insulin therapyAbstract
Background: Pulmonary tuberculosis continues to be a risky comorbidity among patients with type 2 diabetes mellitus, particularly those on long-term insulin therapy. Establishing the prevalence and risk factors of pulmonary tuberculosis in such individuals permits early prevention and detection, mostly in high-prevalence contexts. Objective: To determine the frequency of pulmonary tuberculosis in patients with type 2 diabetes on insulin therapy presenting to MMC Mardan. Study Design: Descriptive cross-sectional study. Duration and Place of Study: This study was conducted from January 2025 to May 2025, in the Department of Pulmonology, MTI-Mardan Medical Complex, Mardan. Methodology: A total of 113 patients aged 30–70 years with a diagnosis of T2DM on insulin therapy for at least 12 months were enrolled. Participants with at least two cardinal symptoms of tuberculosis underwent chest radiography followed by GeneXpert MTB/RIF assay for diagnostic confirmation. Results: The mean age was 49.23±11.61 years and the mean diabetes duration was 9.78±6.25 years. Overall frequency of pulmonary tuberculosis was 11.5% (n=13). Statistically significant associations were observed between PTB and rural residency (p<0.001), as well as smoking status (p<0.001). Conclusion: In our study, we concluded that pulmonary tuberculosis still poses a considerable risk among insulin-dependent type 2 diabetic individuals on insulin, particularly among rural residents and smokers.
Downloads
References
1. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus - conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025;42:102037.
https://doi.org/10.1016/j.bbrep.2025.102037.
2. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;14:1161521.
https://doi.org/10.3389/fendo.2023.1161521.
3. Blaibel D, Fernandez CJ, Pappachan JM. Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: the pathobiology and therapeutic implications. World J Diabetes. 2024;15(3):311-317.
https://doi.org/10.4239/wjd.v15.i3.311.
4. Liu J, Bai R, Chai Z, Cooper ME, Zimmet PZ, Zhang L. Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990-2019 data. Diabetologia. 2022;65(8):1339-1352.
https://doi.org/10.1007/s00125-022-05713-6.
5. Yahaya JJ, Doya IF, Morgan ED, Ngaiza AI, Bintabara D. Poor glycemic control and associated factors among patients with type 2 diabetes mellitus: a cross-sectional study. Sci Rep. 2023;13(1):9673.
https://doi.org/10.1038/s41598-023-36675-3.
6. Al-Sayyar A, Hulme KD, Thibaut R, Bayry J, Sheedy FJ, Short KR, et al. Respiratory tract infections in diabetes - lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Front Endocrinol (Lausanne). 2022;13:919223.
https://doi.org/10.3389/fendo.2022.919223.
7. Vilas-Boas EA, Almeida DC, Roma LP, Ortis F, Carpinelli AR. Lipotoxicity and β-cell failure in type 2 diabetes: oxidative stress linked to NADPH oxidase and ER stress. Cells. 2021;10(12):3328.
https://doi.org/10.3390/cells10123328.
8. Alkabab YM, Al-Abdely HM, Heysell SK. Diabetes-related tuberculosis in the Middle East: an urgent need for regional research. Int J Infect Dis. 2015;40:64-70.
https://doi.org/10.1016/j.ijid.2015.09.010.
9. Abd El-Hamid El-Kady R, Abdulrahman Turkistani S. The footprint of diabetes mellitus on the characteristics and response to anti-tuberculous therapy in patients with pulmonary tuberculosis from Saudi Arabia. Infect Drug Resist. 2021;14:5303-5312.
https://doi.org/10.2147/IDR.S344703.
10. Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPE, Kennedy-Feitosa E, et al. Oxidative stress and inflammation in acute and chronic lung injuries. Antioxidants (Basel). 2023;12(3):548.
https://doi.org/10.3390/antiox12030548.
11. Coetzee A. An introduction to insulin use in type 2 diabetes mellitus. S Afr Fam Pract (2004). 2023;65(1):e1-e5.
https://doi.org/10.4102/safp.v65i1.5702.
12. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S97-S110.
https://doi.org/10.2337/dc23-S006.
13. Berbudi A, Khairani S, Tjahjadi AI. Interplay between insulin resistance and immune dysregulation in type 2 diabetes mellitus: implications for therapeutic interventions. Immunotargets Ther. 2025;14:359-382.
https://doi.org/10.2147/ITT.S499605.
14. Petrelli F, Cangelosi G, Scuri S, Pantanetti P, Lavorgna F, Faldetta F, et al. Diabetes and technology: a pilot study on the management of patients with insulin pumps during the COVID-19 pandemic. Diabetes Res Clin Pract. 2020;169:108481.
https://doi.org/10.1016/j.diabres.2020.108481.
15. Abbas U, Masood KI, Khan A, Irfan M, Saifullah N, Jamil B, et al. Tuberculosis and diabetes mellitus: relating immune impact of co-morbidity with challenges in disease management in high burden countries. J Clin Tuberc Other Mycobact Dis. 2022;29:100343.
https://doi.org/10.1016/j.jctube.2022.100343.
16. Tong X, Wang D, Wang H, Liao Y, Song Y, Li Y, et al. Clinical features in pulmonary tuberculosis patients combined with diabetes mellitus in China: an observational study. Clin Respir J. 2021;15(9):1012-1018.
https://doi.org/10.1111/crj.13405.
17. Alexander M, Cho E, Gliozheni E, Salem Y, Cheung J, Ichii H. Pathology of diabetes-induced immune dysfunction. Int J Mol Sci. 2024;25(13):7105.
https://doi.org/10.3390/ijms25137105.
18. Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S, et al. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian J Endocrinol Metab. 2020;24(1):1-122.
https://doi.org/10.4103/ijem.IJEM_225_20.
19. Ullah H, Iqbal Z, Ullah Z, Mahboob A, Rehman M. Frequency of pulmonary tuberculosis in patients presenting with diabetes. Pak J Chest Med. 2015;15(4):1-7.
20. Mustafa K, Jehangir F, Kamal F, Rafique T, Shah AG, Murtaza I. Prevalence of type 2 diabetes mellitus among pulmonary tuberculosis patients in Pakistan. Pak J Med Dent. 2024;13(4):03-10.
https://doi.org/10.36283/PJMD13-4/002.
21. Chang A, Wu C-Z, Lin J-D, Lee C-N, Tsai K-Y, Wu P-H, et al. Prevalence and risk factors for latent tuberculosis among diabetes patients in Taiwan: a cross-sectional study. J Infect Dev Ctries. 2022;16(4):644-649.
https://doi.org/10.3855/jidc.15839.
22. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152.
https://doi.org/10.1371/journal.pmed.0050152.
23. Chiang C-Y, Lee J-J, Chien S-T, Enarson DA, Chang Y-C, Chen YT, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. PLoS One. 2014;9(4):e93397.
https://doi.org/10.1371/journal.pone.0093397.
24. Shi H, Yuan Y, Li X, Li Y-F, Fan L, Yang X-M. Analysis of the influencing factors and clinical related characteristics of pulmonary tuberculosis in patients with type 2 diabetes mellitus. World J Diabetes. 2024;15(2):196-208.
https://doi.org/10.4239/wjd.v15.i2.196.
25. Fu C-P, Lee C-L, Li Y-H, Lin S-Y. Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: a retrospective cohort study in a single teaching hospital. J Diabetes Investig. 2021;12:1603-1609.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
